Achieving remission may be possible – Learn about the impact FASENRA had on steroid use in patients with EGPA.
59% of patients in a clinical trial were in remission at both 36 and 48 weeks. This means no active EGPA disease activity* and daily oral steroid use of 4 mg or less.
Versus 57% of patients in the control group.
With FASENRA, 41% of people in a clinical study no longer required oral steroids.†‡
Versus 26% of patients in the control group.†‡
86% of patients with EGPA taking FASENRA reduced their dose of oral steroids by 50% or more.†‡
Versus 74% of patients in the control group.†‡
Do not stop or change your corticosteroid medicines unless instructed by your healthcare provider.
Results May Vary
70% of patients in each group remained relapse-free during the study. Relapse is defined as the return of disease symptoms after a period of improvement or remission.
In the 52-week study, FASENRA was studied against mepolizumab (control group, which is an active comparator) in a total of 140 patients (70 for each product). FASENRA was administered 1 injection every 4 weeks, compared with mepolizumab administered 3 injections every 4 weeks. The results across the study were comparable.
*Remission is defined as no active vasculitis and daily oral steroid use of 4 mg or less.
†Oral steroid dose compared to baseline in the last 4 weeks of treatment (weeks 48-52).
‡Based on the design of the study, results are descriptive.
See how FASENRA works
What does FASENRA do?
FASENRA is a biologic medication designed to target and remove eosinophils, which play a role in EGPA.
The mechanism of action of FASENRA in EGPA is not fully understood.
What are eosinophils, and how do they relate to EGPA?
They are white blood cells, a normal part of our immune system. When you have EGPA, a rare autoimmune disorder, your body has too many eosinophils, resulting in inflammation of blood vessels (in tissues and organs). Inflammation and damage to your blood vessels can restrict the amount of blood that reaches tissues and organs throughout your body, which can cause different effects throughout the body and irreversible damage if left untreated.
The mechanism of action of FASENRA in EGPA is not fully understood. FASENRA is a biologic treatment approved to treat EGPA.
FASENRA offers convenient dosing and administration options
FASENRA is the only FDA-approved EGPA treatment that is
ONE INJECTION
EVERY 4 WEEKS§
§Dosing comparisons do not imply improved efficacy or safety.
Administration options include:
At Your Doctor’s Office
Your healthcare provider can administer FASENRA at their office.
At Home
If you and your doctor decide that you will self-administer with the FASENRA Pen, you will receive proper training from a healthcare provider.
Ask your doctor if FASENRA might be right for you
Start the conversation with help from this discussion guide.
Thank you for signing up for FASENRA 360 and for additional information.
FASENRA support materials are on the way based on your communication preferences.
By registering today, I confirm that I am at least 18 years old, agree to receive information about FASENRA, and may receive information about services related to my condition, which includes, but is not limited to, educational and promotional materials, special offers and services, and for market research purposes, which includes contacting me to participate in focus groups, surveys or interviews. This may include AstraZeneca or a third party working on their behalf contacting me by email regarding support programs that may be of interest to me. Information provided by AstraZeneca does not take the place of talking to your healthcare provider about your treatment or condition.
If in the future you no longer want to receive health-related materials, call 1-800-236-9933. Please visit azprivacynotice.com to review our Privacy Notice.
frequently asked questions
FASENRA is a prescription medicine approved to help treat people 18 years and older with EGPA. It's a biologic treatment given by injection once every 4 weeks.
The mechanism of action of FASENRA in EGPA is not fully understood.
The FASENRA prefilled syringe is an injection administered under the skin (subcutaneously) by a healthcare provider.
The FASENRA Pen is an injection administered under the skin (subcutaneously) by the patient, caregiver, or healthcare provider. Do not try to inject the FASENRA Pen until you have been trained by your healthcare provider.
IMPORTANT SAFETY INFORMATION
Do not use FASENRA if you are allergic to benralizumab or any of the ingredients in FASENRA. Do not use to treat sudden breathing problems.
FASENRA may cause serious side effects, including:
- allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your FASENRA injection. Allergic reactions can sometimes happen hours or days after you get your injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- swelling of your face, mouth and tongue
- breathing problems
- fainting, dizziness, feeling lightheaded (low blood pressure)
- rash
- hives
Before using FASENRA, tell your healthcare provider about all of your medical conditions, including if you:
- are taking oral or inhaled corticosteroid medicines. Do not stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back
- have a parasitic (helminth) infection
- are pregnant or plan to become pregnant. It is not known if FASENRA will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with FASENRA
- are breastfeeding or plan to breastfeed. It is not known if FASENRA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use FASENRA
- are taking prescription and over-the-counter medicines, vitamins, or herbal supplements.
Do not stop taking your other medicines unless instructed to do so by your healthcare provider. Tell your healthcare provider if your condition does not get better or if it gets worse after you start treatment with FASENRA.
The most common side effects of FASENRA:
- adults and children 6 years and older with asthma include headache and sore throat
- adults with EGPA include headache
- adults and children 12 years and older with HES include headache, allergic reactions, and flu-like symptoms
These are not all the possible side effects of FASENRA.
APPROVED USE
FASENRA is a prescription medicine used:
- with other asthma medicines for the maintenance treatment of severe asthma in adults and children 6 years and older whose asthma is not controlled with their current asthma medicines. FASENRA is not used to treat sudden breathing problems.
- to treat adults with eosinophilic granulomatosis with polyangiitis (EGPA).
- to treat adults and children 12 years and older with hypereosinophilic syndrome (HES).
Please see full Prescribing Information, including Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products.
